Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chiron gets go ahead to complete pneumonia trial
The committee made its recommendation following a planned interim analysis of clinical data from the study in which no safety concerns were identified. The study is expected to
The committee made its recommendation following a planned interim analysis of clinical data from the study in which no safety concerns were identified. The study is expected to
The trial was designed to compare the safety and efficacy of whole brain radiation therapy alone to brain radiation plus Xcytrin. Although patients receiving Xcytrin had a longer
The results demonstrated a dose related increase in cardiac output of up to 40% with only a 6% increase in heart rate. In addition 7 of 8 patients
Earlier this month, Alnylam initiated its first phase I study in Europe and received clearance of its investigational new drug application by the FDA. Respiratory syncytial virus (RSV)
ViaCell intends to submit information to the investigational review boards at each study site involved in the phase I trial to request immediate resumption of. To date, CB001
In the trial, patients treated with the Dynavax vaccine showed 100% seroprotection compared with 90.5% seroprotection in the group treated with the GSK vaccine. Results also showed that
Eisai Medical Research submitted the revised application after the FDA rejected the original filing, submitted in August 2005, due to deficiencies in its format. Aricept, which is co-promoted
MPL-TLB100 is the first of several products based on the company’s recently acquired compound, MPL-TL, to be entered into clinical testing. The trial will take place at the
The court ruled in Pfizer’s favor in a lawsuit brought by the pharmaceutical giant against the generic manufacturer Ranbaxy. As a result of the decision, Pfizer will be
The combination of Berna and Chiron would offer complementary geographic coverage and product ranges. Novartis would also gain access to Berna’s attractive proprietary technology platforms. A Novartis bid